Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 9 years, with Sep 2025 value amounting to $11.4 million.

  • Ani Pharmaceuticals' Other Non-Current Liabilities fell 43.60% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 43.60%. This contributed to the annual value of $19.8 million for FY2024, which is 17.40% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Other Non-Current Liabilities is $11.4 million, which was down 37.09% from $18.1 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Other Non-Current Liabilities peaked at $35.1 million during Q4 2022, and registered a low of $8.1 million during Q3 2021.
  • In the last 3 years, Ani Pharmaceuticals' Other Non-Current Liabilities had a median value of $13.3 million in 2023 and averaged $15.5 million.
  • In the last 5 years, Ani Pharmaceuticals' Other Non-Current Liabilities surged by 311.95% in 2022 and then crashed by 68.42% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $31.0 million in 2021, then grew by 13.09% to $35.1 million in 2022, then tumbled by 31.54% to $24.0 million in 2023, then declined by 17.40% to $19.8 million in 2024, then tumbled by 43.60% to $11.4 million in 2025.
  • Its Other Non-Current Liabilities was $11.4 million in Q3 2025, compared to $18.1 million in Q2 2025 and $17.4 million in Q1 2025.